Akers Biosciences Acquires Licenses to Coronavirus Vaccine Candidate from Premas Biotech
March 24, 2020 09:00 ET
|
Akers Biosciences Inc.
Established D-Crypt™ platform will be used to develop a proof-of-concept targeting three of the top five viral vaccine protein candidates for CoronavirusCurrent Regulatory environment could lead to...
Akers Biosciences, Inc. Provides Notice of Proposed Settlement of Derivative Litigation
January 17, 2020 17:00 ET
|
Akers Biosciences Inc.
Thorofare, New Jersey, Jan. 17, 2020 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (the “Company”) (NASDAQ: AKER), a developer of rapid health information technologies, today announced that it reached...
Akers BioSciences Regains Compliance with Nasdaq Listing Standards
December 11, 2019 09:30 ET
|
Akers Biosciences Inc.
Thorofare, New Jersey, Dec. 11, 2019 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (the “Company”) (NASDAQ: AKER), a developer of rapid health information technologies, announced today that on...
Akers BioSciences, Inc. Announces Closing of Approximately $8 Million Public Offering
December 09, 2019 11:40 ET
|
Akers Biosciences Inc.
Thorofare, New Jersey, Dec. 09, 2019 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (the “Company” or “we”) (NASDAQ: AKER), a developer of rapid health information technologies, today announced the...
Akers Biosciences to Attend Hemp Industry Daily Forum in Las Vegas, Nevada
December 06, 2019 09:30 ET
|
Akers Biosciences Inc.
Thorofare, New Jersey, Dec. 06, 2019 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (the “Company”) (NASDAQ: AKER), a developer of rapid health information technologies, today announced that Executive...
Akers BioSciences, Inc. Announces Pricing of Approximately $8 Million Public Offering
December 05, 2019 09:25 ET
|
Akers Biosciences Inc.
Thorofare, New Jersey, Dec. 05, 2019 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (the “Company” or “we”) (NASDAQ: AKER), a developer of rapid health information technologies, today announced the...
Akers Biosciences Continues Strategic Review; Explores Leveraging its 30-years of Laboratory Operations to Enter into the Hemp and Minor Cannabinoid Processing Industry
December 05, 2019 08:45 ET
|
Akers Biosciences Inc.
· Establishes Advisory Board appointing Bob Hoban and Michael Patterson Thorofare, New Jersey, Dec. 05, 2019 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (the “Company” or “we”) (NASDAQ:...
Akers Biosciences, Inc. Announces One-for-Twenty Four Reverse Stock Split
November 22, 2019 09:15 ET
|
Akers Biosciences Inc.
THOROFARE, N.J., Nov. 22, 2019 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (NASDAQ: AKER), (“Akers Bio” or the "Company"), a developer of rapid health information technologies, today announced that...
Akers Biosciences Reports Q2 2019 Earnings
August 15, 2019 09:00 ET
|
Akers Biosciences Inc.
Continued Progress Toward Positioning the Company for Strategic Alternatives THOROFARE, N.J., Aug. 15, 2019 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (NASDAQ: AKER) (“Akers Bio” or the...
Akers Biosciences Reports Q1 2019 Earnings
May 20, 2019 17:38 ET
|
Akers Biosciences Inc.
Continued Progress Toward Positioning the Company for Strategic Alternatives THOROFARE, N.J., May 20, 2019 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (NASDAQ: AKER) (“Akers Bio” or the...